News

ImmunoGen has presented positive initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to

Cevec Pharmaceuticals (Cevec) and Inno Biologics have entered into a strategic license agreement. The license enables Inno Biologics to offer the full potential of production of their diagnostic

Roche has reported that the pivotal phase III study, CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab),

Bayer’s consumer care division has begun a voluntary recall of a single product lot of the combination package of Alka-Seltzer Plus day and night cold formula liquid gels,

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has received clearance from the FDA to utilise its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec

MeadWestvaco (MWV) has appointed Peter Durette as the new chief strategy officer and vice president of the company. In this new role, Mr. Durette is expected to oversee

Merck KGaA (Merck) has entered into a strategic alliance with the Deutsche Gesellschaft fur technische Zusammenarbeit (German Technical Cooperation – GTZ). It is intended to improve laboratory chemicals

Medicilon/MPI Preclinical Research-Shanghai has recently expanded their service offerings to provide Sponsors with the ability to conduct studies that meet the FDA’s Good Laboratory Practice (GLP) regulations, at

BHR Pharma (BHR) has filed an Investigational New Drug (IND) application with the FDA for its proprietary BHR-100 intravenous progesterone infusion product. In September of this year, the